These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9759987)

  • 1. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension.
    Hughes D; McGuire A
    J Hum Hypertens; 1998 Aug; 12(8):533-7. PubMed ID: 9759987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Belsey JD
    Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines].
    Fender P; Guilhot J; Tilly B; Salanave B; Allemand H
    Therapie; 2001; 56(2):111-8. PubMed ID: 11471361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.
    Mazzaglia G; Mantovani LG; Sturkenboom MC; Filippi A; Trifirò G; Cricelli C; Brignoli O; Caputi AP
    J Hypertens; 2005 Nov; 23(11):2093-100. PubMed ID: 16208153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
    Schäfer HH; Scheunert U
    Swiss Med Wkly; 2013; 143():w13854. PubMed ID: 24163048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany.
    Breitscheidel L; Ehlken B; Kostev K; Oberdiek MS; Sandberg A; Schmieder RE
    J Med Econ; 2012; 15(1):155-65. PubMed ID: 22035215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving cost-effectiveness of hypertension management at a community health centre.
    Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
    S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
    Jönsson B; Hansson L; Stålhammar NO
    J Intern Med; 2003 Apr; 253(4):472-80. PubMed ID: 12653877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PANDORA project: results of the cost of illness analysis.
    Degli Esposti E; Berto P; Ruffo P; Buda S; Degli Esposti L; Sturani A;
    J Hum Hypertens; 2001 May; 15(5):329-34. PubMed ID: 11378835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of combination therapy on managed care. Based on a presentation by Lisa Latts, MD, MSPH.
    Am J Manag Care; 1999 Jun; 5(7 Suppl):S456-60; discussion S460-2. PubMed ID: 10538854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in compliance among hypertensive patients by drug class: implications for health care costs.
    Rizzo JA; Simons WR
    Clin Ther; 1997; 19(6):1446-57; discussion 1424-5. PubMed ID: 9444452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic challenges in disease management of hypertension.
    Ambrosioni E
    J Hypertens Suppl; 2001 Sep; 19(3):S33-40. PubMed ID: 11713849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health value of fixed-dose combinations in hypertension.
    Ruilope LM; Burnier M; Muszbek N; Brown RE; Keskinaslan A; Ferber P; Harms G
    Blood Press Suppl; 2008 Jun; 1():5-14. PubMed ID: 18705530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of poorly controlled hypertension on healthcare resource utilization and cost.
    Paramore LC; Halpern MT; Lapuerta P; Hurley JS; Frost FJ; Fairchild DG; Bates D
    Am J Manag Care; 2001 Apr; 7(4):389-98. PubMed ID: 11310193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, PharmD.
    Am J Manag Care; 1999 Jun; 5(7 Suppl):S449-53; discussion S453-5. PubMed ID: 10538853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.